Across TCGA pan-cancer cohorts, SP6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SP6 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SP6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SP6 expression acts as an unfavorable survival marker.
KIRP, COAD, and HNSC are the cancer types where SP6 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.